{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:09:06Z","timestamp":1780330146832,"version":"3.54.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1007\/s00120-010-2234-7","type":"journal-article","created":{"date-parts":[[2010,2,23]],"date-time":"2010-02-23T11:21:18Z","timestamp":1266924078000},"page":"181-189","source":"Crossref","is-referenced-by-count":13,"title":["Probleme, Zielsetzung und Inhalt der Fr\u00fcherkennung beim Prostatakarzinom","Problems, objective, and substance of early detection of prostate cancer"],"prefix":"10.1007","volume":"49","author":[{"given":"C.","family":"B\u00f6rgermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Loertzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hammerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Fornara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Graefen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"R\u00fcbben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,2,25]]},"reference":[{"key":"2234_CR1","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","volume":"360","author":"Schroder","year":"2009","unstructured":"Schroder FH, Hugosson J, Roobol MJ et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13):1320\u20131328","journal-title":"N Engl J Med"},{"key":"2234_CR2","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa0810696","volume":"360","author":"Andriole","year":"2009","unstructured":"Andriole GL, Crawford ED, Grubb RL III et al (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13):1310\u20131319","journal-title":"N Engl J Med"},{"key":"2234_CR3","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1097\/01.ju.0000139993.51181.5d","volume":"172","author":"Stamey","year":"2004","unstructured":"Stamey TA, Caldwell M, McNeal JE et al (2004) The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 172(4 Pt 1):1297\u20131301","journal-title":"J Urol"},{"key":"2234_CR4","unstructured":"Brawer MK, Chetner MP (1997) Campell\u2018s urology. Saunders, Philadelphia, pp\u00a02506\u20132518"},{"key":"2234_CR5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.eururo.2005.07.014","volume":"48","author":"Catalona","year":"2005","unstructured":"Catalona WJ, Loeb S (2005) The PSA era is not over for prostate cancer. Eur Urol 48(4):541\u2013545","journal-title":"Eur Urol"},{"key":"2234_CR6","unstructured":"Arbeitsgemeinschaft wissenschaftlich medizinischer Fachgesellschaften (2002) S3-Leitlinie: PSA-Bestimmung in der Prostatakarzinomdiagnostik (Fr\u00fcherkennung des Prostatakarzinoms). http:\/\/www.awmf-online.de"},{"key":"2234_CR7","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/jnci\/djn255","volume":"100","author":"Bill-Axelson","year":"2008","unstructured":"Bill-Axelson A, Holmberg L, Filen F et al (2008) Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 100(16):1144\u20131154","journal-title":"J Natl Cancer Inst"},{"key":"2234_CR8","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1056\/NEJM199608013350502","volume":"335","author":"Morgan","year":"1996","unstructured":"Morgan TO, Jacobsen SJ, McCarthy WF (1996) Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 335(5):304\u2013310","journal-title":"N Engl J Med"},{"key":"2234_CR9","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0090-4295(01)01304-8","volume":"58","author":"Fang","year":"2001","unstructured":"Fang J, Metter EJ, Landis P et al (2001) Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore longitudinal study of aging. Urology 58(3):411\u2013416","journal-title":"Urology"},{"key":"2234_CR10","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.urology.2005.08.040","volume":"67","author":"Loeb","year":"2006","unstructured":"Loeb S, Roehl KA, Antenor JA et al (2006) Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 67(2):316\u2013320","journal-title":"Urology"},{"key":"2234_CR11","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1001\/jama.284.11.1399","volume":"284","author":"Ross","year":"2000","unstructured":"Ross KS, Carter HB, Pearson JD, Guess HA (2000) Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA 284(11):1399\u20131405","journal-title":"JAMA"},{"key":"2234_CR12","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0090-4295(98)00466-X","volume":"53","author":"Carter","year":"1999","unstructured":"Carter HB, Epstein JI, Partin AW (1999) Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. Urology 53(1):126\u2013130","journal-title":"Urology"},{"key":"2234_CR13","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)66929-7","volume":"164","author":"Smith","year":"2000","unstructured":"Smith CV, Bauer JJ, Connelly RR et al (2000) Prostate cancer in men age 50 years or younger: a review of the department of defense center for prostate disease research multicenter prostate cancer database. J Urol 164(6):1964\u20131967","journal-title":"J Urol"},{"key":"2234_CR14","unstructured":"Ries LA, Melbert D, Krapcho M (2008) SEER cancer statistics review, 1975\u20132005, National cancer institute. Bethesda, MD, http:\/\/www.seer.cancer.gov\/csr\/1975_2005"},{"key":"2234_CR15","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1046\/j.1464-410x.2000.00658.x","volume":"85","author":"Horan","year":"2000","unstructured":"Horan AH, McGehee M (2000) Mean time to cancer-specific death of apparently clinically localized prostate cancer: policy implications for threshold ages in prostate-specific antigen screening and ablative therapy. BJU Int 85(9):1063\u20131066","journal-title":"BJU Int"},{"key":"2234_CR16","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1001\/jama.291.22.2713","volume":"291","author":"Johansson","year":"2004","unstructured":"Johansson JE, Andren O, Andersson SO et al (2004) Natural history of early, localized prostate cancer. JAMA 291(22):2713\u20132719","journal-title":"JAMA"},{"key":"2234_CR17","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/jnci\/djj410","volume":"98","author":"Carter","year":"2006","unstructured":"Carter HB, Ferrucci L, Kettermann A et al (2006) Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98(21):1521\u20131527","journal-title":"J Natl Cancer Inst"},{"key":"2234_CR18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.eururo.2007.08.034","volume":"53","author":"Bryant","year":"2008","unstructured":"Bryant RJ, Hamdy FC (2008) Screening for prostate cancer: an update. Eur Urol 53(1):37\u201344","journal-title":"Eur Urol"},{"key":"2234_CR19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-5347(01)65964-0","volume":"156","author":"Albertsen","year":"1996","unstructured":"Albertsen PC, Fryback DG, Storer BE et al (1996) The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 156(1):127\u2013132","journal-title":"J Urol"},{"key":"2234_CR20","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0302-2838(03)00095-2","volume":"43","author":"Oberpenning","year":"2003","unstructured":"Oberpenning F, Hetzel S, Weining C et al (2003) Semi-quantitative immunochromatographic test for prostate specific antigen in whole blood: tossing the coin to predict prostate cancer? Eur Urol 43(5):478\u2013484","journal-title":"Eur Urol"},{"key":"2234_CR21","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1258\/0004563011900632","volume":"38","author":"Price","year":"2001","unstructured":"Price CP, Allard J, Davies G et al (2001) Pre- and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer. Ann Clin Biochem 38(Pt 3):188\u2013216","journal-title":"Ann Clin Biochem"},{"key":"2234_CR22","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/jama.1997.03540420052029","volume":"277","author":"Carter","year":"1997","unstructured":"Carter HB, Epstein JI, Chan DW et al (1997) Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA 277(18):1456\u20131460","journal-title":"JAMA"},{"key":"2234_CR23","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/01.ju.0000165568.76908.5c","volume":"174","author":"Schroder","year":"2005","unstructured":"Schroder FH, Raaijmakers R, Postma R et al (2005) 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam. J Urol 174(2):489\u2013494","journal-title":"J Urol"},{"key":"2234_CR24","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/jnci\/djg057","volume":"95","author":"Cruijsen-Koeter","year":"2003","unstructured":"Cruijsen-Koeter IW van der, Kwast TH van der, Schroder FH (2003) Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. J Natl Cancer Inst 95(19):1462\u20131466","journal-title":"J Natl Cancer Inst"},{"key":"2234_CR25","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.urology.2004.09.046","volume":"65","author":"Roobol","year":"2005","unstructured":"Roobol MJ, Roobol DW, Schroder FH (2005) Is additional testing necessary in men with prostate-specific antigen levels of 1.0\u00a0ng\/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). Urology 65(2):343\u2013346","journal-title":"Urology"},{"key":"2234_CR26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00345-007-0145-z","volume":"25","author":"Bangma","year":"2007","unstructured":"Bangma CH, Roemeling S, Schroder FH (2007) Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol 25(1):3\u20139","journal-title":"World J Urol"},{"key":"2234_CR27","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"D","year":"1998","unstructured":"D\u2019amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969\u2013974","journal-title":"JAMA"},{"key":"2234_CR28","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0022-5347(17)35233-3","volume":"151","author":"Catalona","year":"1994","unstructured":"Catalona WJ, Richie JP, Ahmann FR et al (1994) Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151(5):1283\u20131290","journal-title":"J Urol"},{"key":"2234_CR29","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.juro.2006.10.028","volume":"177","author":"Loeb","year":"2007","unstructured":"Loeb S, Roehl KA, Catalona WJ, Nadler RB (2007) Prostate specific antigen velocity threshold for predicting prostate cancer in young men. J Urol 177(3):899\u2013902","journal-title":"J Urol"},{"key":"2234_CR30","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","volume":"350","author":"Thompson","year":"2004","unstructured":"Thompson IM, Pauler DK, Goodman PJ et al (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level <or =4.0\u00a0ng per milliliter. N Engl J Med 350(22):2239\u20132246","journal-title":"N Engl J Med"},{"key":"2234_CR31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1464-410X.2005.05324.x","volume":"95","author":"Gosselaar","year":"2005","unstructured":"Gosselaar C, Roobol MJ, Schroder FH (2005) Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant? BJU Int 95(2):231\u2013237","journal-title":"BJU Int"},{"key":"2234_CR32","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/01.ju.0000141712.79986.77","volume":"172","author":"Klotz","year":"2004","unstructured":"Klotz L (2004) Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer. J Urol 172(5 Pt 2):48\u201350","journal-title":"J Urol"},{"key":"2234_CR33","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000019578","volume":"33","author":"Djavan","year":"1998","unstructured":"Djavan B, Kadesky K, Klopukh B et al (1998) Gleason scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict Gleason scores of radical prostatectomy specimens. Eur Urol 33(3):261\u2013270","journal-title":"Eur Urol"},{"key":"2234_CR34","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1159\/000020216","volume":"37","author":"Koksal","year":"2000","unstructured":"Koksal IT, Ozcan F, Kadioglu TC et al (2000) Discrepancy between Gleason scores of biopsy and radical prostatectomy specimens. Eur Urol 37(6):670\u2013674","journal-title":"Eur Urol"},{"key":"2234_CR35","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.juro.2006.04.102","volume":"176","author":"Pinthus","year":"2006","unstructured":"Pinthus JH, Witkos M, Fleshner NE et al (2006) Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. J Urol 176(3):979\u2013984","journal-title":"J Urol"},{"key":"2234_CR36","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/modpathol.3800054","volume":"17","author":"Humphrey","year":"2004","unstructured":"Humphrey PA (2004) Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 17(3):292\u2013306","journal-title":"Mod Pathol"},{"key":"2234_CR37","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1001\/jama.1992.03480160073037","volume":"267","author":"Carter","year":"1992","unstructured":"Carter HB, Pearson JD, Metter EJ et al (1992) Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267(16):2215\u20132220","journal-title":"JAMA"},{"key":"2234_CR38","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.urology.2006.09.018","volume":"69","author":"Berger","year":"2007","unstructured":"Berger AP, Deibl M, Strasak A et al (2007) Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer. Urology 69(1):134\u2013138","journal-title":"Urology"},{"key":"2234_CR39","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.urology.2003.09.028","volume":"63","author":"Raaijmakers","year":"2004","unstructured":"Raaijmakers R, Wildhagen MF, Ito K et al (2004) Prostate-specific antigen change in the European randomized study of screening for prostate cancer, section Rotterdam. Urology 63(2):316\u2013320","journal-title":"Urology"},{"key":"2234_CR40","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1373\/clinchem.2004.046086","volume":"51","author":"Soletormos","year":"2005","unstructured":"Soletormos G, Semjonow A, Sibley PE et al (2005) Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin Chem 51(8):1342\u20131351","journal-title":"Clin Chem"},{"key":"2234_CR41","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.eururo.2009.07.048","volume":"56","author":"Vickers","year":"2009","unstructured":"Vickers AJ, Wolters T, Savage CJ et al (2009) Prostate-specific antigen velocity for early detection of prostate cancer: Result from a large, representative, population-based cohort. Eur Urol 56:761\u2013762","journal-title":"Eur Urol"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-010-2234-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-010-2234-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-010-2234-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T15:48:09Z","timestamp":1558626489000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-010-2234-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["2234"],"URL":"https:\/\/doi.org\/10.1007\/s00120-010-2234-7","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}